Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient
- 1 September 2015
- journal article
- case report
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 90 (9) , 1294-1297
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplantHepatology, 2015
- Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case reportWorld Journal of Gastroenterology, 2015
- Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity”American Journal of Transplantation, 2014
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Cost Analysis of Sofosbuvir/Ribavirin Versus Sofosbuvir/Simeprevir for Genotype 1 Hepatitis C Virus in Interferon-Ineligible/Intolerant IndividualsHepatology, 2014
- Update on Recently Approved Treatments for Hepatitis CCurrent Treatment Options in Gastroenterology, 2014
- Second‐wave IFN‐based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvirLiver International, 2013
- Causes and Prognosis of Diffuse Alveolar Damage Diagnosed on Surgical Lung BiopsyChest, 2007
- The association between hepatitis C infection and survival after orthotopic liver transplantationGastroenterology, 2002
- Long-Term Outcome of Hepatitis C Infection after Liver TransplantationNew England Journal of Medicine, 1996